Home LiteratureArticle Details
PMID: 28343267 Published · ppublish English Journal Article

Tumor-Associated Macrophages and Regulatory T Cells Infiltration and the Clinical Outcome in Colorectal Cancer.

Archivum immunologiae et therapiae experimentalis ·Vol. 65 ·No. 5 ·2017-10-00 ·Pages 445-454

Waniczek D, Lorenc Z, Śnietura M, Wesecki M, Kopec A, Muc-Wierzgoń M

Abstract

The aim of the study is the assessment of the intensity of the infiltration of tumor-associated macrophages (TAMs) CD68+/iNOS- and Tregs CD8+/FoxP3+ in colorectal cancer (CRC) patients as prognostic factors with respect to disease-free survival (DFS) and overall survival (OS). In this retrospective study, tissue samples were obtained from 89 patients undergoing resection for CRC (stage IIA, pT3N0M0 and stages IIIB and IIIC, pT3N1-2M0). Recurrence was observed in 45 patients at the time of the follow-up (10 local recurrences, 35 distant metastases). In patients with recurrence the following were present: a tendency to an older average age at the time of diagnosis (p = 0.07), higher nodal involvement (p = 0.002) and more advanced clinical disease (p = 0.01). The analysis of the clinical data and immunohistochemical studies were performed with the methodology of identification of TAM and Treg subsets in histological sections, with the aim to use it in routine clinical management. Both DSF and OS were the clinical parameters assessed in the study. The presence of intense infiltration of TAMs in the tumor stroma was related to shorter DFS (p = 0.005) and OS (p = 0.006). The opposite tendency was observed in the tumor front (p = 0.061). The relative risks of recurrence and cancer-related death were more than twice higher in the group of patients with intense infiltration of TAMs in the tumor stroma (RR 2.05, 95% CI 1.33-3.14; p = 0.001 and RR 2.08, 95% CI 1.28-3.39; p = 0.003, respectively). Intense infiltration of Tregs in the tumor stroma was related to shorter DFS and OS (p < 0.0001). The relative risks of recurrence and death in a group of patients with intense infiltration of Tregs in the tumor stroma were more than 12 times higher than in patients with less intense infiltration (RR 12.3, 95% CI 5.44-27.9; p < 0.0001 and RR 12.5, 95% CI 4.9-32.4; p < 0.0001, respectively). Infiltration of TAMs CD68+/iNOS- and Tregs CD8+/FoxP3+ in the tumor stroma are negative prognostic factors with a positive correlation between them. Tregs may constitute an independent prognostic factor in patients with CRC.

Keywords
Colorectal cancer Regulatory lymphocytes TAMs Tregs Tumor-associated macrophages
MeSH Terms
Adult Aged Aged, 80 and over Cell Movement Colonic Neoplasms/diagnosis,immunology,mortality Colorectal Neoplasms/diagnosis,immunology,mortality Female Follow-Up Studies Humans Macrophages/immunology Male Middle Aged Neoplasm Staging Predictive Value of Tests Prognosis Recurrence Risk Survival Analysis T-Lymphocytes, Regulatory/immunology Treatment Outcome
Authors & Affiliations
6 authors, click to expand affiliations / ORCID
Waniczek Dariusz
SHS in Katowice, Department of Propaedeutics Surgery, Chair of General, Colorectal and Polytrauma Surgery, Medical University of Silesia in Katowice, Żeromskiego 7, 41-902, Bytom, Poland.
Lorenc Zbigniew
SHS in Katowice, Chair of General, Colorectal and Polytrauma Surgery, Medical University of Silesia in Katowice, Plac Medyków 1, 41-200, Sosnowiec, Poland.
Śnietura Mirosław
Tumor Pathology Department, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Armii Krajowej 15, 44-100, Gliwice, Poland.
Wesecki Mariusz
SHS in Katowice, Chair of General, Colorectal and Polytrauma Surgery, Medical University of Silesia in Katowice, Plac Medyków 1, 41-200, Sosnowiec, Poland.
Kopec Agnieszka
Tumor Pathology Department, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Armii Krajowej 15, 44-100, Gliwice, Poland.
Muc-Wierzgoń Małgorzata
Department of Internal Medicine, Medical University of Silesia in Katowice, Żeromskiego 7, 41-902, Bytom, Poland. mwierzgon@sum.edu.pl.
References (33)
33 references, click to expand
  1. Effector memory T cells, early metastasis, and survival in colorectal cancer.
    N Engl J Med. 2005 Dec 22;353(25):2654-66 PMID: 16371631
  2. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.
    Int J Cancer. 2015 Mar 1;136(5):E359-86 PMID: 25220842
  3. Increased frequency of regulatory T cells in peripheral blood and tumour infiltrating lymphocytes in colorectal cancer patients.
    Cancer Immun. 2007 Mar 28;7:7 PMID: 17388261
  4. FOXP3 expression in tumor cells and tumor-infiltrating lymphocytes is associated with breast cancer prognosis.
    Mol Clin Oncol. 2013 Jul;1(4):625-632 PMID: 24649219
  5. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection.
    J Clin Oncol. 2007 Jun 20;25(18):2586-93 PMID: 17577038
  6. Expression of Foxp3 in colorectal cancer but not in Treg cells correlates with disease progression in patients with colorectal cancer.
    PLoS One. 2013;8(1):e53630 PMID: 23382847
  7. FOXP3+ regulatory T cells affect the development and progression of hepatocarcinogenesis.
    Clin Cancer Res. 2007 Feb 1;13(3):902-11 PMID: 17289884
  8. High macrophage infiltration along the tumor front correlates with improved survival in colon cancer.
    Clin Cancer Res. 2007 Mar 1;13(5):1472-9 PMID: 17332291
  9. Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions.
    Clin Cancer Res. 2006 Sep 15;12(18):5423-34 PMID: 17000676
  10. Hypoxia-inducible factor-1alpha expression correlates with focal macrophage infiltration, angiogenesis and unfavourable prognosis in urothelial carcinoma.
    J Clin Pathol. 2008 May;61(5):658-64 PMID: 17908805
  11. FOXP3 expression and overall survival in breast cancer.
    J Clin Oncol. 2009 Apr 10;27(11):1746-52 PMID: 19255331
  12. The role of FOXP3 in disease progression in colorectal cancer patients.
    Oncoimmunology. 2013 Jun 1;2(6):e24521 PMID: 23894712
  13. Expression of FOXP3 in esophageal squamous cell carcinoma relating to the clinical data.
    Dis Esophagus. 2010 May;23(4):340-6 PMID: 19788437
  14. Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human colorectal cancer.
    Cancer Immun. 2007 Feb 21;7:4 PMID: 17311363
  15. The Role of Cathelicidin LL-37 in Cancer Development.
    Arch Immunol Ther Exp (Warsz). 2016 Feb;64(1):33-46 PMID: 26395996
  16. Prognostic significance of cell infiltrations of immunosurveillance in colorectal cancer.
    World J Gastroenterol. 2005 Feb 28;11(8):1210-4 PMID: 15754407
  17. Coordinated regulation of myeloid cells by tumours.
    Nat Rev Immunol. 2012 Mar 22;12(4):253-68 PMID: 22437938
  18. Type and location of tumor-infiltrating macrophages and lymphatic vessels predict survival of colorectal cancer patients.
    Int J Cancer. 2012 Aug 15;131(4):864-73 PMID: 21952788
  19. High density of FOXP3-positive T cells infiltrating colorectal cancers with microsatellite instability.
    Br J Cancer. 2008 Dec 2;99(11):1867-73 PMID: 18985040
  20. Correlations of tumor-associated macrophage subtypes with liver metastases of colorectal cancer.
    Asian Pac J Cancer Prev. 2013;14(2):1003-7 PMID: 23621176
  21. Antigen-nonspecific activation of CD8+ T lymphocytes by cytokines: relevance to immunity, autoimmunity, and cancer.
    Arch Immunol Ther Exp (Warsz). 2008 Sep-Oct;56(5):311-23 PMID: 18836862
  22. B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma.
    J Exp Med. 2006 Apr 17;203(4):871-81 PMID: 16606666
  23. The density of macrophages in the invasive front is inversely correlated to liver metastasis in colon cancer.
    J Transl Med. 2010 Feb 08;8:13 PMID: 20141634
  24. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome.
    Science. 2006 Sep 29;313(5795):1960-4 PMID: 17008531
  25. Regulatory T cells, tumour immunity and immunotherapy.
    Nat Rev Immunol. 2006 Apr;6(4):295-307 PMID: 16557261
  26. Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer.
    J Clin Oncol. 2009 Jan 10;27(2):186-92 PMID: 19064967
  27. The density of macrophages in colorectal cancer is inversely correlated to TGF-β1 expression and patients' survival.
    J Mol Histol. 2013 Dec;44(6):679-92 PMID: 23801404
  28. Macrophage infiltration and its prognostic implications in breast cancer: the relationship with VEGF expression and microvessel density.
    Oncol Rep. 2005 Aug;14(2):425-31 PMID: 16012726
  29. CD4+CD25+ regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression.
    Cancer. 2003 Sep 1;98(5):1089-99 PMID: 12942579
  30. Identification of CD8+CD25+Foxp3+ suppressive T cells in colorectal cancer tissue.
    Gut. 2009 Apr;58(4):520-9 PMID: 19022917
  31. In situ analysis of FOXP3+ regulatory T cells in human colorectal cancer.
    J Transl Med. 2006 Dec 13;4:52 PMID: 17166272
  32. Specific metabolic biomarkers as risk and prognostic factors in colorectal cancer.
    World J Gastroenterol. 2014 Aug 7;20(29):9759-74 PMID: 25110413
  33. Prognostic role of FOXP3+ regulatory T cells infiltrating human carcinomas: the paradox of colorectal cancer.
    Cancer Immunol Immunother. 2011 Jul;60(7):909-18 PMID: 21644034
Article Info
Journal
Archivum immunologiae et therapiae experimentalis
Abbr.
Arch Immunol Ther Exp (Warsz)
ISSN
1661-4917
Published
2017-10-00
Epub
2017-00-25
Pages
445-454
Language
English
Region
Switzerland
NLM ID
0114365
PMCID
PMC5602054
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com